# US 2003/0215824 A1 · XAF genes and polypeptides: methods and reagents for modulating apoptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215824 A1
- Document ID: US20030215824A1
- Status: Published application
- Kind: A1
- Application number: 10/288,273
- Filed: 2002-11-05
- Published: 2003-11-20
- Earliest claimed: 1997-07-14
- Assignees: Aegera Therapeutics, Inc.
- Inventors: Robert G. Korneluk; Katsuyuki Tamai; Peter Liston; Alexander E. MacKenzie
- Web page: https://patentgrep.com/patent/US20030215824A1

## CPC

- A61K 38/1709: {from mammals}
- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 14/4747: {Apoptosis related proteins}
- C07K 16/18: against material from animals or humans
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5017: {for testing neoplastic activity}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.

## Claims

### Claim 1

A method of identifying a compound that modulates apoptosis, said method comprising:
(a) providing a cell comprising a XAF gene; and
(b) contacting said cell with a candidate compound; and
(c) monitoring expression of said AAF gene, an alteration in the level of expression of said gene indicating a compound which modulates apoptosis.

### Claim 2

A method of identifying a compound that modulates apoptosis, said method comprising:
(a) providing a cell comprising a reporter gene operably linked to a promoter from a XAF gene;
(b) contacting said cell with a candidate compound; and
(c) measuring expression of said reporter gene, an alteration in said expression in response to said candidate compound identifying a compound that is able to modulate apoptosis.

### Claim 3

A method of identifying a compound that is able to inhibit XAF-mediated apoptosis, said method comprising the steps of:
(a) providing a cell expressing an apoptosis-inducing amount of XAF;
(b) contacting said cell with a candidate compound; and
(c) measuring level of apoptosis in said cell, a decrease in said level relative to a level in a cell not contacted with said candidate compound indicating a compound that able to inhibit XAF-mediated apoptosis.

### Claim 4

A method of identifying a compound that is able to induce XAF-mediated apoptosis, said method comprising the steps of:
(a) providing a cell expressing an apoptosis-inducing amount of XAF;
(b) contacting said cell with a candidate compound; and
(c) measuring level of apoptosis in said cell, an increase in said level relative to a level in a cell not contacted with said candidate compound indicating a compound that able to induce XAF-mediated apoptosis.

### Claim 5

A method of identifying a compound that modulates apoptosis, said method comprising:
(a) providing a cell expressing a TRAF polypeptide, a XAF polypeptide, and a reporter gene operably linked to DNA comprising an NF-κB binding site;
(b) contacting said cell with a candidate compound; and
(c) measuring expression of said reporter gene, a change in expression in response to said compound indicating said compound is able to modulate apoptosis.

### Claim 6

A method of identifying a compound that modulates apoptosis, said method comprising:
(a) providing a cell expressing a TRAF polypeptide, a XAF polypeptide, an IAP polypeptide, and a reporter gene operably linked to DNA comprising an NF-κB binding site;
(b) contacting said cell with a candidate compound; and
(c) measuring expression of said reporter gene, a change in expression in response to said compound indicating said compound is able to modulate apoptosis.

### Claim 7

A method for detecting a compound capable of modulating apoptosis, said method comprising:
(a) providing a cell having:
(i) a reporter gene operably linked to a DNA-binding-protein recognition site;
(ii) a first fusion gene capable of expressing a first fusion protein, said first fusion protein comprising a XAF polypeptide covalently bonded to a binding moiety, said binding moiety capable of specifically binding to said DNA-binding-protein recognition site;
(iii) a second fusion gene capable of expressing a second fusion protein, said second fusion protein comprising a second XAF polypeptide covalently bonded to a gene activating moiety;
(b) exposing said cell to said compound; and
(c) measuring reporter gene expression in said cell, a change in said reporter gene expression indicating said compound is capable of modulating apoptosis.

### Claim 8

A method for detecting a compound capable of modulating apoptosis, said method comprising:
(a) providing a cell having:
(i) a reporter gene operably linked to a DNA-binding-protein recognition site;
(ii) a first fusion gene capable of expressing a first fusion protein, said first fusion protein comprising a XAF polypeptide covalently bonded to a binding moiety, said binding moiety capable of specifically binding to said DNA-binding-protein recognition site;
(iii) a second fusion gene capable of expressing a second fusion protein, said second fusion protein comprising an IAP polypeptide covalently bonded to a gene activating moiety;
(b) exposing said cell to said compound; and
(c) measuring reporter gene expression in said cell, a change in said reporter gene expression indicating said compound is capable of modulating apoptosis.

### Claim 9

A method for detecting a compound capable of modulating apoptosis, said method comprising:
(a) providing a cell having:
(i) a reporter gene operably linked to a DNA-binding-protein recognition site;
(ii) a first fusion gene capable of expressing a first fusion protein, said first fusion protein comprising an IAP polypeptide covalently bonded to a binding moiety, said binding moiety capable of specifically binding to said DNA-binding-protein recognition site;
(iii) a second fusion gene capable of expressing a second fusion protein, said second fusion protein comprising a XAF polypeptide covalently bonded to a gene activating moiety;
(b) exposing said cell to said compound; and
(c) measuring reporter gene expression in said cell, a change in said reporter gene expression indicating said compound is capable of modulating apoptosis.

### Claim 10

A method for detecting a compound capable of modulating apoptosis, said method comprising:
(a) providing a first XAF polypeptide, said first XAF polypeptide immobilized on a solid-phase substrate;
(b) contacting said first XAF polypeptide with a second XAF polypeptide;
(c) contacting said first XAF polypeptide and said second XAF polypeptide with a compound; and
(d) measuring amount of binding of said first XAF polypeptide to said second XAF polypeptide, a change in said amount relative to an amount not contacted with said compound indicating said compound is capable of modulating apoptosis.

### Claim 11

A method for detecting a compound capable of modulating apoptosis, said method comprising:
(a) providing a XAF polypeptide, said XAF polypeptide immobilized on a solid-phase substrate;
(b) contacting said XAF polypeptide with an TAP polypeptide;
(c) contacting said XAF polypeptide and said TAP polypeptide with a compound; and
(d) measuring amount of binding of said XAF polypeptide to said TAP polypeptide, a change in said amount relative to an amount not contacted with said compound indicating said compound is capable of modulating apoptosis.

### Claim 12

A method for detecting a compound capable of modulating apoptosis, said method comprising:
(a) providing an TAP polypeptide, said TAP polypeptide immobilized on a solid-phase substrate;
(b) contacting said IAP polypeptide with a XAF polypeptide;
(c) contacting said IAP polypeptide and said XAF polypeptide with a compound; and
(d) measuring amount of binding of said IAP polypeptide to said XAF polypeptide, a change in said amount relative to an amount not contacted with said compound indicating said compound is capable of modulating apoptosis.
